AI Engines For more Details: Perplexity Kagi Labs You
Histamine H3 Receptor Modulation: Thioperamide maleate selectively blocks the histamine H3 receptor, which is involved in the modulation of histamine release and neurotransmitter activity in the brain. By antagonizing these receptors, thioperamide maleate can modulate neurotransmitter release, including histamine, dopamine, serotonin, and norepinephrine, among others.
Neuroscientific Research: Thioperamide maleate is primarily used as a research tool in neuroscience to study the role of histamine H3 receptors in various physiological and pathological processes. Its selective antagonism of these receptors allows researchers to investigate the effects of histamine modulation on neurotransmission, behavior, cognition, and other neurobiological functions.
Cognitive Enhancement: Histamine H3 receptors are known to modulate cognitive function, arousal, and attention. Antagonism of these receptors by compounds like thioperamide maleate has been investigated for its potential cognitive-enhancing effects. Preclinical studies have suggested that histamine H3 receptor antagonists may improve cognitive performance in animal models, raising interest in their potential therapeutic applications for cognitive disorders such as Alzheimer's disease and attention deficit hyperactivity disorder (ADHD).
Wakefulness Promotion: Histamine H3 receptor antagonists have also been studied for their potential wake-promoting effects. By increasing histamine release and neurotransmitter activity in wake-promoting brain regions, thioperamide maleate and other histamine H3 receptor antagonists may have utility in the treatment of sleep disorders such as narcolepsy and excessive daytime sleepiness.
Potential Therapeutic Applications: While thioperamide maleate itself is not used therapeutically in medical practice, its pharmacological effects on histamine H3 receptors have implications for the development of novel treatments for neurological and psychiatric disorders. By understanding the mechanisms of action of thioperamide maleate and related compounds, researchers may identify new drug targets and therapeutic strategies for conditions involving dysregulation of histaminergic neurotransmission.
| Rank | Probiotic | Impact |
|---|---|---|
| genus | Bifidobacterium | Reduces |
| species | Akkermansia muciniphila | Reduces |
| species | Bacteroides uniformis | Reduces |
| species | Bifidobacterium longum | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| subspecies | Bifidobacterium longum subsp. infantis | Reduces |
| subspecies | Bifidobacterium longum subsp. longum | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.6 | 0.6 | |
| Acne | 0.3 | -0.3 | |
| ADHD | 1.9 | 0.6 | 2.17 |
| Age-Related Macular Degeneration and Glaucoma | 1.1 | 1.1 | |
| Allergic Rhinitis (Hay Fever) | 1.5 | 0.8 | 0.88 |
| Allergies | 2.4 | 0.7 | 2.43 |
| Allergy to milk products | 0.9 | 0.6 | 0.5 |
| Alopecia (Hair Loss) | 1 | 1 | |
| Alzheimer's disease | 2.5 | 3 | -0.2 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 1.7 | 0.1 | 16 |
| Ankylosing spondylitis | 1.6 | 0.5 | 2.2 |
| Anorexia Nervosa | 0.4 | 1.7 | -3.25 |
| Antiphospholipid syndrome (APS) | 0.3 | 0.3 | 0 |
| Asthma | 3.3 | 1.2 | 1.75 |
| Atherosclerosis | 1 | 0.8 | 0.25 |
| Atrial fibrillation | 2 | 1 | 1 |
| Autism | 4.5 | 3.5 | 0.29 |
| Autoimmune Disease | 0.3 | 0.8 | -1.67 |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Biofilm | 0.2 | 0.2 | |
| Bipolar Disorder | 0.9 | 1.1 | -0.22 |
| Brain Trauma | 0.6 | 1.1 | -0.83 |
| Cancer (General) | 0.3 | 1.1 | -2.67 |
| Carcinoma | 2.4 | 1.9 | 0.26 |
| Celiac Disease | 0.7 | 2.3 | -2.29 |
| Cerebral Palsy | 0.6 | 1 | -0.67 |
| Chronic Fatigue Syndrome | 2.1 | 2.8 | -0.33 |
| Chronic Kidney Disease | 2 | 1.8 | 0.11 |
| Chronic Lyme | 0.1 | 0.8 | -7 |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.3 | 0.8 | -1.67 |
| Chronic Urticaria (Hives) | 0.2 | -0.2 | |
| Coagulation / Micro clot triggering bacteria | 0.7 | -0.7 | |
| Cognitive Function | 2 | 1.1 | 0.82 |
| Colorectal Cancer | 2.6 | 1.7 | 0.53 |
| Constipation | 0.3 | 0.7 | -1.33 |
| Coronary artery disease | 0.8 | 1.8 | -1.25 |
| COVID-19 | 4.4 | 5.4 | -0.23 |
| Crohn's Disease | 3.7 | 3.1 | 0.19 |
| Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
| cystic fibrosis | 1.3 | -1.3 | |
| deep vein thrombosis | 0.5 | 0.8 | -0.6 |
| Depression | 5.6 | 4.7 | 0.19 |
| Dermatomyositis | 0.3 | -0.3 | |
| Eczema | 0.2 | 0.4 | -1 |
| Endometriosis | 1.6 | 1.1 | 0.45 |
| Epilepsy | 1.2 | 0.8 | 0.5 |
| erectile dysfunction | 0.3 | 0.3 | 0 |
| Fibromyalgia | 2.3 | 0.6 | 2.83 |
| Functional constipation / chronic idiopathic constipation | 1.8 | 2 | -0.11 |
| gallstone disease (gsd) | 1 | 0.9 | 0.11 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.1 | 0.6 | -5 |
| Generalized anxiety disorder | 1.2 | 1.3 | -0.08 |
| Gout | 0.7 | 0.3 | 1.33 |
| Graves' disease | 0.9 | 2.4 | -1.67 |
| Gulf War Syndrome | 0.4 | 0.8 | -1 |
| Halitosis | 0.3 | 0.3 | |
| Hashimoto's thyroiditis | 2.2 | 1.1 | 1 |
| Heart Failure | 0.8 | 1.2 | -0.5 |
| hemorrhagic stroke | 0.6 | 0.6 | |
| Hidradenitis Suppurativa | 0.6 | 0.6 | |
| High Histamine/low DAO | 0.5 | 0.3 | 0.67 |
| hypercholesterolemia (High Cholesterol) | 0.3 | 0.1 | 2 |
| hyperglycemia | 0.6 | 0.8 | -0.33 |
| Hyperlipidemia (High Blood Fats) | 0.9 | 0.3 | 2 |
| hypersomnia | 0.7 | -0.7 | |
| hypertension (High Blood Pressure | 1.9 | 3.2 | -0.68 |
| Hypothyroidism | 0 | 1 | 0 |
| Hypoxia | 1.2 | 0.3 | 3 |
| IgA nephropathy (IgAN) | 0.6 | 1.4 | -1.33 |
| Inflammatory Bowel Disease | 2.9 | 3.9 | -0.34 |
| Insomnia | 1.3 | 1.4 | -0.08 |
| Intelligence | 0.6 | 0.6 | |
| Intracranial aneurysms | 0.4 | 0.6 | -0.5 |
| Irritable Bowel Syndrome | 3.1 | 1.9 | 0.63 |
| ischemic stroke | 1.1 | 1.1 | 0 |
| Liver Cirrhosis | 3.6 | 3 | 0.2 |
| Long COVID | 3.1 | 4.9 | -0.58 |
| Low bone mineral density | 0.8 | -0.8 | |
| Lung Cancer | 0.4 | 0.8 | -1 |
| Mast Cell Issues / mastitis | 0.6 | -0.6 | |
| ME/CFS with IBS | 0.1 | 1.4 | -13 |
| ME/CFS without IBS | 1.1 | 1.3 | -0.18 |
| Menopause | 0.5 | 0.6 | -0.2 |
| Metabolic Syndrome | 4.1 | 3.9 | 0.05 |
| Mood Disorders | 5.1 | 3.7 | 0.38 |
| multiple chemical sensitivity [MCS] | 0 | 0.1 | 0 |
| Multiple Sclerosis | 3.1 | 2 | 0.55 |
| Multiple system atrophy (MSA) | 0.3 | 0.4 | -0.33 |
| myasthenia gravis | 0.5 | -0.5 | |
| neuropathic pain | 0.3 | 1.6 | -4.33 |
| Neuropathy (all types) | 0.5 | 0.8 | -0.6 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.3 | 0.3 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.7 | 3.1 | -0.15 |
| NonCeliac Gluten Sensitivity | 1.4 | 0.6 | 1.33 |
| Obesity | 5.4 | 4.8 | 0.13 |
| obsessive-compulsive disorder | 1.2 | 2.6 | -1.17 |
| Osteoarthritis | 1.1 | 0.6 | 0.83 |
| Osteoporosis | 1.1 | 1.1 | 0 |
| pancreatic cancer | 0.3 | 0.3 | |
| Parkinson's Disease | 4.6 | 3.2 | 0.44 |
| Polycystic ovary syndrome | 2.5 | 1.9 | 0.32 |
| Postural orthostatic tachycardia syndrome | 0.6 | -0.6 | |
| Premenstrual dysphoric disorder | 0.7 | 0.7 | |
| primary biliary cholangitis | 0.6 | 0.3 | 1 |
| Primary sclerosing cholangitis | 0.3 | 1.2 | -3 |
| Psoriasis | 1.1 | 1.3 | -0.18 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 4.1 | 3 | 0.37 |
| Rosacea | 0.5 | 0.5 | 0 |
| Schizophrenia | 2.7 | 1.6 | 0.69 |
| scoliosis | 0.3 | 0.3 | 0 |
| Sjögren syndrome | 0.4 | 1.6 | -3 |
| Sleep Apnea | 1.3 | 1.5 | -0.15 |
| Slow gastric motility / Gastroparesis | 0.3 | 0.3 | 0 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.6 | 0.4 | 0.5 |
| Stress / posttraumatic stress disorder | 1.7 | 2.4 | -0.41 |
| Systemic Lupus Erythematosus | 1.9 | 1.3 | 0.46 |
| Tic Disorder | 0.3 | 1.2 | -3 |
| Tourette syndrome | 0.6 | 0.3 | 1 |
| Type 1 Diabetes | 1.3 | 1.9 | -0.46 |
| Type 2 Diabetes | 4.4 | 3 | 0.47 |
| Ulcerative colitis | 1.9 | 2.8 | -0.47 |
| Unhealthy Ageing | 2.5 | 1.6 | 0.56 |
| Vitiligo | 0.7 | 0.4 | 0.75 |
